Antes de empezar

viernes, 16 de marzo de 2012

http://clinicaltrials.gov/ct2/show/NCT01556802?term=minocycline+stroke&rank=5
Use of Minocicline in Patients With Stroke
This study is currently recruiting participants.
Verified March 2012 by Hospital Universitario Hernando Moncaleano Perdomo

First Received on March 5, 2012.   Last Updated on March 15, 2012   History of Changes
Sponsor:Hospital Universitario Hernando Moncaleano Perdomo
Information provided by
 (Responsible Party):
Nataly Bedoya, Hospital Universitario Hernando Moncaleano Perdomo
ClinicalTrials.gov Identifier:NCT01556802
  Purpose
The investigators will evaluate the National Institute of Health Stroke Scale/Score (NIHSS)in patients with stroke, and then give Minocycline 100mg po every 12 hours or placebo for five days, then perform periodic evaluations to determine the status and degree of neurological sequelae developed.

ConditionInterventionPhase
Stroke
Brain Ischemia
Paralysis
Drug: Minocicline
Drug: Placebo
Phase I

Study Type:Interventional
Study Design:Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title:Effect of Minocicline Use in Less Neurologic Sequels in Patients With Stroke

Resource links provided by NLM:


Further study details as provided by Hospital Universitario Hernando Moncaleano Perdomo:

Primary Outcome Measures:
  • To determine the efficacy of minocycline in reducing neurological sequelae in patients with stroke [ Time Frame: one year ] [ Designated as safety issue: No ]
    The researchers evaluated the neurological condition of paralysis, aphasia,and level of consciousness by NIHSS score for each patient with stroke and proceeded to give minocycline or placebo. Then, the assessment was repeated after five and thirty days post treatment to determine whether their neurological sequelae had diminushed.

Secondary Outcome Measures:
  • Identify the side effects of the intervention administered during the treatment time and 30 days later. [ Time Frame: one year ] [ Designated as safety issue: Yes ]

Estimated Enrollment:134
Study Start Date:October 2011
Estimated Study Completion Date:January 2013
Primary Completion Date:November 2011 (Final data collection date for primary outcome measure)
ArmsAssigned Interventions
Experimental: Minocicline
minocicline 100mg oral twice a day for 5 days
Drug: Minocicline
Minocicline 100mg oral twice a day for 5 days
Placebo Comparator: Placebo
Pills filled with vegetal fiber with similar presentation of the drug. Given one pill oral twice a day for five days
Drug: Placebo
Pills with vegetable fibers one pill oral twice a day for five days

  Eligibility

Ages Eligible for Study:  18 Years to 85 Years
Genders Eligible for Study:  Both
Accepts Healthy Volunteers:  No
Criteria
Inclusion Criteria:
  • NIHSS scale greater than 5
  • Onset of symptoms less than 24 hours
  • normal Cranial Tomography(CT)
  • CT evidence of cerebral ischemia
  • Acceptance of study entry
Exclusion Criteria:
  • Hemorrhagic cerebrovascular disease
  • Other neurological diseases
  • Concomitant structural damage
  • History of neurosurgery
  • Known allergy to tetracyclines
  • Concomitant infectious diseases requiring antibiotic treatment.
  • History of Stroke
  • Women pregnant or breast-feeding
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01556802

Contacts
Contact: Nataly Bedoya, md
nata0916@hotmail.com


Locations
Colombia
University Hospital hernando Moncaleano PerdomoRecruiting
Neiva, Huila, Colombia
Contact: Nataly Bedoya, Md.         nata0916@hotmail.com    
Sponsors and Collaborators
Hospital Universitario Hernando Moncaleano Perdomo
Investigators
Study Director:Nataly Bedoya, InternistUniversidad Surcolombiana
Principal Investigator:Hernan Vargas, InternistUniversidad Surcolombiana
Principal Investigator:Hugo Osorio, InternistUniversidad Surcolombiana
Principal Investigator:Guillermo Gonzalez, NeurologistUniversidad Surcolombiana
Principal Investigator:Javier Saldaña, EpidemiologyUniversidad Surcolombiana
Principal Investigator:Efrain Amaya, NeurologistHospital Hernando Moncaleano Perdomo
  More Information

No publications provided 

Responsible Party:Nataly Bedoya, Internist, Hospital Universitario Hernando Moncaleano Perdomo
ClinicalTrials.gov Identifier:NCT01556802     History of Changes
Other Study ID Numbers:38212050
Study First Received:March 5, 2012
Last Updated:March 15, 2012
Health Authority:Colombia: National Institutes of Health

Keywords provided by Hospital Universitario Hernando Moncaleano Perdomo:
stroke
sequelaes
minocicline

Additional relevant MeSH terms:
Stroke
Cerebral Infarction
Brain Ischemia
Ischemia
Paralysis
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Infarction
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on March 15, 2012







3 comentarios:

Anónimo dijo...

Link exchange is nothing else however it is only placing
the other person's webpage link on your page at proper place and other person will also do similar in favor of you.

Also visit my site http://wingmanworld.Com

Anónimo dijo...

Aw, this was an extremely nice post. Finding the time and actual effort
to create a good article… but what can I say…
I procrastinate a whole lot and never manage to get nearly anything done.


Feel free to visit my page ... ranger forum

Anónimo dijo...

Link exchange is nothing else however it is simply placing the other person's webpage link on your page at proper place and other person will also do same in favor of you.

My site - ford ranger forum